Therapeutic area intelligence for Overactive Bladder with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Quadrant Pharmaceuticals →

Assets

Mirabegron →

Vesomni →

Recent signals(3)

RegulatoryAugust 2, 2026

FDA Approval Application for Mirabegron Submitted by Deva Holding

The FDA has received an application (ANDA219941) for Mirabegron from Deva Holding, currently under standard review.

StrategyJuly 12, 2026

FDA Grants Approval for Mirabegron ANDA219941 by Deva Holding AS

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219941 for Mirabegron submitted by Deva Holding AS.

RegulatoryJune 28, 2026

Quadrant Pharmaceuticals Issues Class 4 Medicines Defect Notification for Vesomni Tablets

Quadrant Pharmaceuticals has reported Class 4 Medicines Defect due to incorrect barcode/GTIN on Vesomni tablets.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.